Literature DB >> 17433075

Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.

Denise Morais da Fonseca1, Célio Lopes Silva, Marina Oliveira e Paula, Edson Garcia Soares, Gilles Marchal, Cynthia Horn, Vânia Luiza Deperon Bonato.   

Abstract

The results of various animal model studies of tuberculosis (TB) suggest that culture filtrate proteins (CFPs), which are antigens secreted by Mycobacterium tuberculosis, are largely responsible for improvements in TB vaccines. The great obstacle to developing protein subunit vaccines is that adjuvants are required in order to stimulate relevant protective immune responses. Acting as immune adjuvants, CpG-oligodeoxynucleotides (CpG-ODNs) promote the activation of Th1 cells and of pro-inflammatory cytokines. To evaluate the adjuvant role of CpG-ODNs in conferring enhanced immunogenic capacity and protection against M. tuberculosis, we immunized mice with CFP antigen combined with synthetic CpG-ODNs (CFP/CpG) or with incomplete Freund's adjuvant (IFA) (CFP/IFA). Immunization with CFP/CpG induced a T helper 1 (Th1)-biased response accompanied by a higher immunoglobulin G2a (IgG2a) antibody/IgG1 antibody ratio, elevated production of interferon-gamma (IFN-gamma) by spleen cells and in lungs. However, CFP/IFA-immunized mice presented higher levels of IgG1 antibodies, as well as increased production of IFN-gamma, interleukin (IL)-5, and IL-10 by spleen cells, together with lower levels of IFN-gamma in the lungs. Despite the stronger Th1 response seen in both groups, believed to be necessary for protection against TB, only mice immunized with CFP/IFA were protected after M. tuberculosis infection. Lung histology revealed that lung parenchyma were better preserved in CFP/IFA-immunized mice, which also presented intense lymphocyte recruitment to the lesion, whereas CFP/CpG-immunized mice presented severe pulmonary injury accompanied by necrosis. Based on the data presented, we discuss the widely accepted paradigm that high levels of IFN-gamma are directly correlated with protection against experimental TB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17433075      PMCID: PMC2265969          DOI: 10.1111/j.1365-2567.2007.02597.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  51 in total

Review 1.  Targeting the innate immune response with improved vaccine adjuvants.

Authors:  Achal Pashine; Nicholas M Valiante; Jeffrey B Ulmer
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

2.  Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.

Authors:  R Hernandez-Pando; L Pavön; K Arriaga; H Orozco; V Madrid-Marina; G Rook
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

3.  Therapy of tuberculosis in mice by DNA vaccination.

Authors:  D B Lowrie; R E Tascon; V L Bonato; V M Lima; L H Faccioli; E Stavropoulos; M J Colston; R G Hewinson; K Moelling; C L Silva
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

4.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.

Authors:  Jan A M Langermans; T Mark Doherty; Richard A W Vervenne; Tridia van der Laan; Konstantin Lyashchenko; Rena Greenwald; Else Marie Agger; Claus Aagaard; Horst Weiler; Dick van Soolingen; Wilfried Dalemans; Alan W Thomas; Peter Andersen
Journal:  Vaccine       Date:  2005-04-15       Impact factor: 3.641

5.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

6.  Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.

Authors:  Z K Ballas; W L Rasmussen; A M Krieg
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

Review 7.  Advances in tuberculosis vaccine strategies.

Authors:  Yasir A W Skeiky; Jerald C Sadoff
Journal:  Nat Rev Microbiol       Date:  2006-06       Impact factor: 60.633

Review 8.  Do successful tuberculosis vaccines need to be immunoregulatory rather than merely Th1-boosting?

Authors:  Graham A W Rook; Keertan Dheda; Alimuddin Zumla
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

9.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

10.  Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype.

Authors:  V Rao; N Dhar; H Shakila; R Singh; A Khera; R Jain; M Naseema; C N Paramasivan; P R Narayanan; V D Ramanathan; A K Tyagi
Journal:  Scand J Immunol       Date:  2005-05       Impact factor: 3.487

View more
  7 in total

1.  Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+) /CD4(+)  Foxp3(+) cells.

Authors:  Paola Fernanda Fedatto; Cássia Alves Sérgio; Marina Oliveira e Paula; Ana Flávia Gembre; Luís Henrique Franco; Pryscilla Fanini Wowk; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Walter Miguel Turato; Célio Lopes Silva; Denise Morais da Fonseca; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

2.  A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.

Authors:  Dyego Carlétti; Denise Morais da Fonseca; Ana Flávia Gembre; Ana Paula Masson; Lívia Weijenborg Campos; Luciana C C Leite; Andréa Rodrigues Pires; Joseli Lannes-Vieira; Célio Lopes Silva; Vânia Luiza Deperon Bonato; Cynthia Horn
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

Review 3.  Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.

Authors:  Else Marie Agger
Journal:  Adv Drug Deliv Rev       Date:  2015-11-17       Impact factor: 15.470

4.  Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.

Authors:  Denise Morais da Fonseca; Celio Lopes Silva; Pryscilla Fanini Wowk; Marina Oliveira E Paula; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Vânia Luiza Deperon Bonato
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

5.  CCR4-dependent reduction in the number and suppressor function of CD4+Foxp3+ cells augments IFN-γ-mediated pulmonary inflammation and aggravates tuberculosis pathogenesis.

Authors:  Thais B Bertolini; Annie R Piñeros; Rafael Q Prado; Ana Flávia Gembre; Leandra N Z Ramalho; José Carlos Alves-Filho; Vânia L D Bonato
Journal:  Cell Death Dis       Date:  2018-12-21       Impact factor: 8.469

6.  Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.

Authors:  Else Marie Agger; Ida Rosenkrands; Jon Hansen; Karima Brahimi; Brian S Vandahl; Claus Aagaard; Kerstin Werninghaus; Carsten Kirschning; Roland Lang; Dennis Christensen; Michael Theisen; Frank Follmann; Peter Andersen
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

7.  Protection against tuberculosis by a single intranasal administration of DNA-hsp65 vaccine complexed with cationic liposomes.

Authors:  Rogério S Rosada; Lucimara Gaziola de la Torre; Fabiani G Frantz; Ana P F Trombone; Carlos R Zárate-Bladés; Denise M Fonseca; Patrícia R M Souza; Izaíra T Brandão; Ana P Masson; Edson G Soares; Simone G Ramos; Lúcia H Faccioli; Célio L Silva; Maria H A Santana; Arlete A M Coelho-Castelo
Journal:  BMC Immunol       Date:  2008-07-22       Impact factor: 3.615

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.